{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:27:39Z","timestamp":1787509659533,"version":"build-2736575974"},"reference-count":65,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>The prevalence of human papillomavirus (HPV)-related diseases in women has declined in countries introducing HPV vaccinations for girls but remains high among men. The objective of this study was to compare the health impact and cost-effectiveness of two HPV vaccination strategies in the pre-adolescent Taiwanese population: nonavalent (9vHPV) gender-neutral vaccination (GNV), and 9vHPV female-only vaccination (FOV). A previously validated dynamic transmission model was adapted to the Taiwanese setting. The model had a 100-year time horizon and assumed an 85% vaccination coverage rate for girls and a 50% rate for boys, lifelong duration of vaccine protection, herd immunity, and a discount rate of 3% for costs and quality-adjusted life-years (QALYs). Costs of vaccination and HPV-related disease (in 2015\u22122016 new Taiwan dollars [NTD]), QALYs, and incremental cost-effectiveness ratios (ICERs) were estimated. Compared to 9vHPV FOV, GNV prevented 572 additional cases of cervical cancer (a 1.0% decrease) and 57,691 cases of genital warts (\u221212.6%) in women. In men, 26 additional cases of penile cancer were avoided (\u22126.6%), as well as 179,207 cases of genital warts (\u221226.7%), 4,955 cases of head and neck cancer (\u22129.0%), and 3,880 cases of recurrent respiratory papillomatosis (\u221215.8%), by use of the 9vHPV GNV strategy versus FOV. Use of 9vHPV GNV instead of FOV would prevent 229 deaths from cervical cancer in women (a 0.6% decrease) and 3,398 deaths from head and neck cancer in men (\u22128.3%) over 100 years. The 9vHPV GNV strategy resulted in a savings of NTD 1,574,288,155 (1.9%) in disease management costs compared to the 9vHPV FOV strategy and was predicted to be cost-effective, with an ICER of NTD 606,210\/QALY. Compared to a 9vHPV FOV strategy, a 9vHPV GNV strategy for 13-year-old girls and boys would result in incremental public health and economic benefits and would be cost-effective in Taiwan.<\/jats:p>","DOI":"10.1371\/journal.pone.0333757","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T17:27:11Z","timestamp":1760462831000},"page":"e0333757","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Health impact and cost-effectiveness analysis of gender-neutral versus female-only 9-valent human papillomavirus vaccination in Taiwan"],"prefix":"10.1371","volume":"20","author":[{"given":"Hung-Hsueh","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pen-Yuan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2281-5852","authenticated-orcid":true,"given":"Ying-Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0568-8145","authenticated-orcid":true,"given":"Isaya","family":"Sukarom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pavelyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"pone.0333757.ref001","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"LE Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"pone.0333757.ref002","article-title":"Global burden of human papillomavirus and related diseases","author":"D Forman","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"pone.0333757.ref003","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv403","article-title":"HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients","volume":"108","author":"X Castellsagu\u00e9","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"33","key":"pone.0333757.ref004","doi-asserted-by":"crossref","first-page":"918","DOI":"10.15585\/mmwr.mm6733a2","article-title":"Trends in Human Papillomavirus-Associated Cancers - United States, 1999-2015","volume":"67","author":"EA Van Dyne","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pone.0333757.ref005","unstructured":"Health Promotion Administration, Ministry of Health and Welfare. Cancer Registry Annual Report. 2017."},{"issue":"2","key":"pone.0333757.ref006","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ijc.29330","article-title":"Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995-2009","volume":"137","author":"T-Z Hwang","year":"2015","journal-title":"Int J Cancer"},{"issue":"3","key":"pone.0333757.ref007","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.27354","article-title":"Human papillomavirus in vaginal intraepithelial neoplasia","volume":"131","author":"A Chao","year":"2012","journal-title":"Int J Cancer"},{"issue":"4","key":"pone.0333757.ref008","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky045","article-title":"Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6\/11\/16\/18\/31\/33\/45\/52 and 58","volume":"2","author":"S de Sanjos\u00e9","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"8","key":"pone.0333757.ref009","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/jmv.22111","article-title":"Analyses of human papillomavirus genotypes and viral loads in anogenital warts","volume":"83","author":"SLR Ball","year":"2011","journal-title":"J Med Virol"},{"issue":"3","key":"pone.0333757.ref010","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/ijc.26404","article-title":"Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China","volume":"131","author":"PKS Chan","year":"2012","journal-title":"Int J Cancer"},{"key":"pone.0333757.ref011","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bpobgyn.2017.08.006","article-title":"Epidemiology and burden of HPV-related disease","volume":"47","author":"B Serrano","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"9","key":"pone.0333757.ref012","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/ijc.22538","article-title":"Human papillomavirus genotype in cervical cancer: a population-based study","volume":"120","author":"C-H Lai","year":"2007","journal-title":"Int J Cancer"},{"issue":"1","key":"pone.0333757.ref013","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41598-019-57177-1","article-title":"Clinical characteristics and treatment outcome of oropharyngeal squamous cell carcinoma in an endemic betel quid region","volume":"10","author":"T-C Chen","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"pone.0333757.ref014","article-title":"Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?","volume":"22","author":"EA Joura","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"pone.0333757.ref015","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(16)30001-9","article-title":"Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models","volume":"1","author":"M Brisson","year":"2016","journal-title":"Lancet Public Health"},{"issue":"10197","key":"pone.0333757.ref016","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"M Drolet","year":"2019","journal-title":"Lancet"},{"key":"pone.0333757.ref017","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e13108","article-title":"Global burden of HPV-related cancers in men: A systematic literature review","volume":"37","author":"S Varga","year":"2019","journal-title":"JCO"},{"issue":"1","key":"pone.0333757.ref018","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1186\/s12885-022-09407-5","article-title":"Rising incidence of HPV positive oropharyngeal cancer in Taiwan between 1999 and 2014 where betel nut chewing is common","volume":"22","author":"C-P Wang","year":"2022","journal-title":"BMC Cancer"},{"key":"pone.0333757.ref019","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pvr.2015.06.007","article-title":"Seroconversion Following Anal and Genital HPV Infection in Men: The HIM Study","volume":"1","author":"AR Giuliano","year":"2015","journal-title":"Papillomavirus Res"},{"key":"pone.0333757.ref020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.pvr.2015.09.001","article-title":"An analysis of HPV infection incidence and clearance by genotype and age in men: The HPV Infection in Men (HIM) Study","volume":"1","author":"DJ Ingles","year":"2015","journal-title":"Papillomavirus Res"},{"issue":"42","key":"pone.0333757.ref021","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"EH Elbasha","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"pone.0333757.ref022","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"EH Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"pone.0333757.ref023","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/epirev\/mxj006","article-title":"Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease","volume":"28","author":"EJ Dasbach","year":"2006","journal-title":"Epidemiol Rev"},{"issue":"5","key":"pone.0333757.ref024","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1136\/ijgc-00009577-200609000-00013","article-title":"The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions: A Taiwan Cooperative Oncologic Group Study","volume":"16","author":"C-A Chen","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"pone.0333757.ref025","article-title":"Clinical impact of human papillomavirus in laryngeal squamous cell carcinoma: a retrospective study","volume":"5","author":"W-C Chen","year":"2017","journal-title":"PeerJ"},{"issue":"47","key":"pone.0333757.ref026","article-title":"Human Papillomavirus Infections are Common and Predict Mortality in a Retrospective Cohort Study of Taiwanese Patients With Oral Cavity Cancer","volume":"94","author":"L-A Lee","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"pone.0333757.ref027","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1071\/SH17013","article-title":"Estimating the burden of genital warts in Taiwan","volume":"14","author":"T-F Tsai","year":"2017","journal-title":"Sex Health"},{"key":"pone.0333757.ref028","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13027-017-0129-6","article-title":"Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe","volume":"12","author":"S Hartwig","year":"2017","journal-title":"Infect Agent Cancer"},{"issue":"2","key":"pone.0333757.ref029","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1473-3099(17)30653-9","article-title":"Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis","volume":"18","author":"C Lin","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"pone.0333757.ref030","article-title":"Oropharyngeal squamous cell carcinoma is associated with high-risk human papillomavirus in Taiwan","author":"CW Liao","year":"2019","journal-title":"AACR-AHNS: American Association for Cancer Research"},{"issue":"5","key":"pone.0333757.ref031","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.eururo.2015.12.007","article-title":"Role of Human Papillomavirus in Penile Carcinomas Worldwide","volume":"69","author":"L Alemany","year":"2016","journal-title":"Eur Urol"},{"key":"pone.0333757.ref032","unstructured":"Progress Report Ministry of Health and Welfare, Executive Yuan, R.O.C (Taiwan). [Accessed September 12, 2022]. https:\/\/www.mohw.gov.tw\/cp-12-63771-1.html"},{"issue":"7","key":"pone.0333757.ref033","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1136\/sextrans-2012-050980","article-title":"HPV vaccine acceptability among men: a systematic review and meta-analysis","volume":"89","author":"PA Newman","year":"2013","journal-title":"Sex Transm Infect"},{"key":"pone.0333757.ref034","unstructured":"Cancer Australia. HPV Vaccination Uptake. https:\/\/ncci.canceraustralia.gov.au\/prevention\/hpv-vaccination-uptake\/hpv-vaccination-uptake"},{"key":"pone.0333757.ref035","unstructured":"Department of Household Registration, Ministry of the Interior, Republic of China (Taiwan). Statistics. [Accessed November 28, 2022]. https:\/\/www.ris.gov.tw\/app\/en\/3910"},{"key":"pone.0333757.ref036","unstructured":"Health Promotion Administration, Ministry of Health and Welfare. Cervical Cancer Screening Registry System Annual Report, Republic of China. 2018. [Accessed November 28, 2022]. https:\/\/www.hpa.gov.tw\/Pages\/List.aspx?nodeid=1322"},{"issue":"12","key":"pone.0333757.ref037","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1002\/ijc.23441","article-title":"Cervical cancer screening program integrating Pap smear and HPV DNA testing: a population-based study","volume":"122","author":"A Chao","year":"2008","journal-title":"Int J Cancer"},{"key":"pone.0333757.ref038","unstructured":"National Health Insurance Research Database, Taiwan. [Accessed November 29, 2022]. http:\/\/nhird.nhri.org.tw\/en\/index.htm"},{"issue":"19","key":"pone.0333757.ref039","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"SM Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0333757.ref040","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"AR Giuliano","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0333757.ref041","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"EA Joura","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"pone.0333757.ref042","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"JM Palefsky","year":"2011","journal-title":"N Engl J Med"},{"issue":"9576","key":"pone.0333757.ref043","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"KA Ault","year":"2007","journal-title":"Lancet"},{"issue":"9574","key":"pone.0333757.ref044","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"EA Joura","year":"2007","journal-title":"Lancet"},{"key":"pone.0333757.ref045","unstructured":"Taiwan Ministry of Health. Taiwan Cancer Registry. [Accessed June 3, 2022]. https:\/\/twcr.tw\/?page_id=1843&lang=en"},{"key":"pone.0333757.ref046","unstructured":"Health Promotion Administration. [Accessed November 28, 2022]. https:\/\/www.hpa.gov.tw\/Pages\/ashx\/File.ashx?FilePath=~\/File\/Attach\/16056\/File_19682.pdf;"},{"key":"pone.0333757.ref047","unstructured":"National Statistics. Directorate-General of Budget, Accounting and Statistics, Executive Yuan, R.O.C (Taiwan), [Accessed September 7, 2022]. https:\/\/www.stat.gov.tw\/public\/data\/dgbas03\/bs4\/Statistical%20Tables\/table(043).xls"},{"key":"pone.0333757.ref048","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1472-6963-10-11","article-title":"Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan","volume":"10","author":"P-H Liu","year":"2010","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"pone.0333757.ref049","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.31557\/APJCP.2019.20.5.1377","article-title":"Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan","volume":"20","author":"C-H Tang","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"pone.0333757.ref050","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jval.2012.02.012","article-title":"Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan","volume":"15","author":"N Demarteau","year":"2012","journal-title":"Value Health"},{"key":"pone.0333757.ref051","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.vhri.2022.06.006","article-title":"The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan","volume":"32","author":"H-H Chou","year":"2022","journal-title":"Value Health Reg Issues"},{"issue":"3","key":"pone.0333757.ref052","first-page":"459","article-title":"The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan","volume":"9","author":"EJ Dasbach","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"key":"pone.0333757.ref053","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1080\/21645515.2018.1560770","article-title":"Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain","volume":"15","author":"J De La Fuente","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"pone.0333757.ref054","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.vaccine.2020.10.089","article-title":"Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France","volume":"39","author":"L Majed","year":"2021","journal-title":"Vaccine"},{"key":"pone.0333757.ref055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12962-017-0073-8","article-title":"Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy","volume":"15","author":"FS Mennini","year":"2017","journal-title":"Cost Eff Resour Alloc"},{"key":"pone.0333757.ref056","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2407-13-10","article-title":"Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe","volume":"13","author":"R Marty","year":"2013","journal-title":"BMC Cancer"},{"issue":"1","key":"pone.0333757.ref057","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s12879-019-4108-y","article-title":"Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK","volume":"19","author":"S Datta","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"19","key":"pone.0333757.ref058","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.vaccine.2018.03.024","article-title":"Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination","volume":"36","author":"SS Ng","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"pone.0333757.ref059","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.4161\/hv.29137","article-title":"HPV vaccination in boys and men","volume":"10","author":"M Stanley","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"pone.0333757.ref060","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00103-018-2791-2","article-title":"Background paper for the recommendation of HPV vaccination for boys in Germany","volume":"61","author":"A Takla","year":"2018","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"3","key":"pone.0333757.ref061","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.2017.75.0141","article-title":"Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States","volume":"36","author":"AK Chaturvedi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14","key":"pone.0333757.ref062","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.vaccine.2022.02.067","article-title":"Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom","volume":"40","author":"V Daniels","year":"2022","journal-title":"Vaccine"},{"issue":"11","key":"pone.0333757.ref063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0310591","article-title":"Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low\/middle-income countries: An analysis of Indonesia","volume":"19","author":"V Daniels","year":"2024","journal-title":"PLoS One"},{"issue":"2","key":"pone.0333757.ref064","doi-asserted-by":"crossref","first-page":"2184605","DOI":"10.1080\/21645515.2023.2184605","article-title":"Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong","volume":"19","author":"TH Cheung","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"pone.0333757.ref065","unstructured":"Ministry of Health and Welfare. 114\u5e74\u5ea6\u885b\u751f\u798f\u5229\u7279\u5225\u6536\u5165\u57fa\u91d1\u9644\u5c6c\u55ae\u4f4d\u9810\u7b97\u6848 114 Annual Health and Welfare Special Income Fund Subsidiary Unit Budget. [Accessed June 19, 2025]. https:\/\/dep.mohw.gov.tw\/DOA\/cp-650-79793-112.html"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0333757","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T17:27:22Z","timestamp":1760462842000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0333757"}},"subtitle":[],"editor":[{"given":"Emmanuel Timmy","family":"Donkoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":65,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0333757","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]}}}